Press releases
- Marinus Pharmaceuticals Announces Ganaxolone Approved in China as First Treatment for Seizures Associated with CDKL5 Deficiency Disorder
- Marinus Pharmaceuticals Announces Topline Results from Phase 3 RAISE Trial of IV Ganaxolone in Refractory Status Epilepticus
- Marinus Pharmaceuticals Announces Key Business Updates for Tuberous Sclerosis Complex Program
- Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results
- Marinus Pharmaceuticals to Present at the RBC Capital Markets 2024 Global Healthcare Conference
- Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2024 Financial Results on May 8, 2024
More ▼
Key statistics
As of last trade, Marinus Pharmaceuticals Inc (61Y:STU) traded at 1.29, 20.56% above the 52 week low of 1.07 set on Jul 05, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.28 |
---|---|
High | 1.31 |
Low | 1.28 |
Bid | 1.29 |
Offer | 1.32 |
Previous close | 1.30 |
Average volume | 666.67 |
---|---|
Shares outstanding | 54.93m |
Free float | 54.38m |
P/E (TTM) | -- |
Market cap | 77.73m USD |
EPS (TTM) | -2.64 USD |
Data delayed at least 15 minutes, as of Jul 25 2024.
More ▼